Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7,771–782 (2008).
  Medline CASGoogle Scholar
• 2  Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature464,1067–1070 (2010).
  Medline CASGoogle Scholar
• 3  Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab.10,836–841 (2009).
  Medline CASGoogle Scholar
• 4  Gordon EM, Lopez FF, Cornelio GH et al. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. Int. J. Oncol.29,1053–1064 (2006).
  Medline CASGoogle Scholar
• 5  Libutti SK, Paciotti GF, Byrnes AA et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res.16,6139–6149 (2010).
  Medline CASGoogle Scholar
• 6  Wesselinova D. Current major cancer targets for nanoparticle systems. Curr. Cancer Drug Targets11,164–183 (2011).
  Medline CASGoogle Scholar
• 7  Zhang L, Gu FX, Chan JM et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther.83,761–769 (2008).
  Medline CASGoogle Scholar
• 8  Ali I, Rahis-Uddin, Salim K et al. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets11,135–146 (2011).
  Medline CASGoogle Scholar
• 9  Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7,771–782 (2008).
  Medline CASGoogle Scholar
• 10  Ow H, Larson D, Srivastava M et al. Bright and stable core-shell fluorescent silica nanoparticles. Nano Lett.5,113–117 (2005).
  Medline CASGoogle Scholar
• 11  Benezra M, Penate-Medina O, Zanzonico PB et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest.121(7),2768–2780 (2011).
  Medline CASGoogle Scholar
• 12  Tilocca A. Models of structure, dynamics and reactivity of bioglasses: a review. J. Mater. Chem.20,6848–6858 (2010).
  CASGoogle Scholar
• 13  Unger KK, Rupprecht H, Valentin B et al. The use of porous and surface modified silicas as drug delivery and stabilizing agents. Drug Development Ind. Pharm.9,69–91 (1983).
  CASGoogle Scholar
• 14  Simovic S, Ghouchu-Eskandar N, Sinn AM et al. Silica materials in drug delivery applications. Curr. Drug Deliv. Technol.8(3),269–276 (2011).
  MedlineGoogle Scholar
• 15  Manzano M, Colilla M, Vallet-Regi M. Drug delivery from ordered mesoporous matrices. Expert Opin. Drug Del.6,1383–1400 (2009).
  Medline CASGoogle Scholar
• 16  Rosenholm JM, Sahlgren C, Lindén M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles – opportunities and challenges. Nanoscale2,1870–1883 (2010).
  Medline CASGoogle Scholar
• 17  He QJ, Shi JL. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem.21,5845–5855 (2011)
  CASGoogle Scholar
• 18  Vivero-Escoto JL, Slowing II, Trewyn BG et al. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small6,1952–1967 (2010).
  Medline CASGoogle Scholar
• 19  Santos, HA; Salonen, J; Bimbo, LM et al. Mesoporous materials as controlled drug delivery formulations. J. Drug Delivery Sci. Tech.21,139–155 (2011).
  CASGoogle Scholar
• 20  Mellaerts R, Mols R, Jammaer JAG et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm.69,223–230 (2008).
  Medline CASGoogle Scholar
• 21  Vallet-Regi M, Balas F, Colilla M et al. Bone-regenerative bioceramic implants with drug and protein controlled delivery capability. Progr. Solid State Chem.36,163–191 (2008).
  CASGoogle Scholar
• 22  Dai C, Yuan Y, Liu C et al. Degradable, antibacterial silver exchanged mesoporous silica spheres for hemorrhage control. Biomaterials30,5364–5374 (2009).
  Medline CASGoogle Scholar
• 23  López T, Basaldella EI, Ojeda MJ et al. Encapsulation of valproic acid and sodic phenytoin in ordered mesoporous SiO₂ solids for the treatment of temporal lope epilepsy. Optical Mater.29,75–81 (2006).
  CASGoogle Scholar
• 24  Wu SH, Lin YS, Hung Y et al. Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies. Chem. Bio. Chem.9,53–57 (2008).▪ The first report on in vivo application of mesoporous silica nanoparticles. MagDye@ mesoporous silica nanoparticles (MSNs) for MRI used for cellular tracking after transplantation of prelabeled cells and biodistribution after intravenous injections. Highlights the problem of elimination from specific organs.
  CASGoogle Scholar
• 25  Lin YS, Wu SH, Hung Y et al. Multifunctional composite nanoparticles: magnetic, luminescent, and mesoporous. Chem. Mater.18,5170–5172 (2006).
  CASGoogle Scholar
• 26  Liu HM, Wu SH, Lu CW et al. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells. Small4,619–626 (2008).
  Medline CASGoogle Scholar
• 27  Lu CW, Hung Y, Hsiao JK et al. Bifunctional magnetic silica nanoparticles for highly efficient human stem cell labeling. Nano Lett.7,149 (2007).
  Medline CASGoogle Scholar
• 28  Hsiao JK, Tsai CP, Chung TH et al. Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small4,1445–1452, (2008).
  Medline CASGoogle Scholar
• 29  Steinbacher JL, Lathrop SA, Cheng K et al. Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. Small6,2678–2682 (2010).
  Medline CASGoogle Scholar
• 30  Taylor KM, Kim JS, Reiter WJ et al. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J. Am. Chem. Soc.130,2154–2155 (2008).
  Medline CASGoogle Scholar
• 31  Lee CH, Cheng SH, Wang YJ et al. Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution. Adv. Funct. Mater.19,215–222 (2009).
  CASGoogle Scholar
• 32  He Q, Zhang Z, Gao F et al.In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small7,271–280 (2011).▪▪ Continuation of the study by Lin et al. elucidating how different surface functionalizations and size affect lifetime and biodistribution. The study emphasized the need for using different techniques to determine biodistribution and tissue accumulation.
  Medline CASGoogle Scholar
• 33  Huang X, Li L, Liu T et al. The shape effect of Mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano5(7),5390–5399 (2011).
  Medline CASGoogle Scholar
• 34  Kim J, Kim HS, Lee N et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed.47,8438–8441 (2008).
  Medline CASGoogle Scholar
• 35  Lee JE, Lee N, Kim H et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J. Am. Chem. Soc.132,552–557 (2010).
  Medline CASGoogle Scholar
• 36  Lu J, Liong M, Li Z et al. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small6,1794–1805 (2010).
  Medline CASGoogle Scholar
• 37  Meng H, Xue M, Xia T et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano5,4131–4144 (2011).
  Medline CASGoogle Scholar
• 38  Mamaeva V, Rosenholm JM, Bate-Eya LT et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol. Ther.19,1538–1546 (2011).▪ This is, to the best of our knowledge, the first study introducing a promising drug class that has not passed clinical trials due to severe side effects, where the use of targetable mesoporous silica nanoparticles proved beneficial.
  Medline CASGoogle Scholar
• 39  Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug delivery system: enhanced efficacy by folate modification. Nanomed. Nanotech. Biol. Med. doi:10.1016/j.nano.2011.06.002 (2011) (Epub ahead of print).
  Google Scholar
• 40  Etienne M, Walcarius A. Analytical investigation of the chemical reactivity and stability of aminopropyl-grafted silica in aqueous medium. Talanta59,1173–1188 (2003).
  Medline CASGoogle Scholar
• 41  Cauda V, Schlossbauer A, Bein T. Bio-degradation study of colloidal mesoporous silica nanoparticles: effect of surface functionalization with organo-silanes and poly(ethylene glycol). Microporous Mesoporous Mater.132,60–71 (2010).
  CASGoogle Scholar
• 42  Mortera R, Fiorilli S, Garrone E et al. Pore occlusion in MCM-41 spheres immersed in SBF and the effect on ibuprofen delivery kinetics: a quantitative model. Chem. Eng. J.156,184–192 (2010).
  CASGoogle Scholar
• 43  Martin KR. The chemistry of silica and its potential health benefits. J. Nutr. Health Aging11,94–97 (2007).
  Medline CASGoogle Scholar
• 44  Souris JS, Lee CH, Cheng SH et al. Surface charge-mediated rapid hepatobiliary exretion of mesoporous silica nanoparticles. Biomaterials31,5564–5574 (2010).
  Medline CASGoogle Scholar
• 45  Hillegass JM, Blumen SR, Cheng K et al. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int. J. Cancer.129,233–244 (2011).
  Medline CASGoogle Scholar
• 46  Wang T, Chai F, Q. Fu et al. Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy, J. Mater. Chem.21,5299–5306 (2011).
  Google Scholar
• 47  Huang IP, Sun SP, Cheng SH et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol. Cancer Ther.10,761–769 (2011).
  Medline CASGoogle Scholar
• 48  Lee S, Yun H-S, Kim S-H. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials32(35),9434–9443 (2011).
  Medline CASGoogle Scholar
• 49  Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. Chem. Mater.21,3979–3986 (2009).
  CASGoogle Scholar
• 50  Slowing II, Wu CW, Vivero-Escoto JL et al. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small5,57–62 (2009).
  Medline CASGoogle Scholar
• 51  Zhao Y, Sun X, Zhang G et al. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano5,1366–1375 (2011).
  Medline CASGoogle Scholar
• 52  Hudson SP, Padera RF, Langer R et al. The biocompatibility of mesoporous silicates. Biomaterials29,4045–4055 (2008).▪ Demonstrated high toxicity of nonfunctionalized silica-based particles in vivo. Later studies addressing size, methods of synthesis and surface functionalization porosity, highlighted MSNs as a technology of value and well worth considering for medical applications.
  Medline CASGoogle Scholar
• 53  Huang X, Zhuang J, Teng X et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials31,6142–6153 (2010).
  Medline CASGoogle Scholar
• 54  Liu T, Li L, Teng X et al. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials32,1657–1668 (2011).
  Medline CASGoogle Scholar
• 55  Tao Z, Morrow MP, Asefa T et al. Mesoporous silica nanoparticles inhibit cellular respiration. Nano Lett.8,1517–1526 (2008).
  Medline CASGoogle Scholar
• 56  Al Shamsi M, Al Samri MT, Al-Salam S et al. Biocompatibility of calcined mesoporous silica particles with cellular bioenergetics in murine tissues. Chem. Res. Toxicol.23,1796–1805 (2010).
  Medline CASGoogle Scholar
• 57  Huang X, Zhuang J, Teng X et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species Biomaterials31,6142–6153 (2010).
  Medline CASGoogle Scholar
• 58  Luo T, Huang P, Gao G et al. Mesoporous silica-coated gold nanorods with embedded indocyanine green for dual mode x-ray and NIR fluorescence imaging. Optics Express19,17030–17039 (2011).
  Medline CASGoogle Scholar
• 101  Epeius Biotechnologies. www.epeiusbiotech.com
  Google Scholar
• 102  Silicon Dioxide GRAS Notification. www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000321.pdf
  Google Scholar